Table 3.
Difference in concentrations of plasma biomarkers between study groups (pravastatin versus placebo) over the 3-year study period compared with the baseline
| Variable (Δ) | Pravastatin | Placebo | P Value |
|---|---|---|---|
| Asymmetric dimethylarginine, µM | 0.07±0.09 | 0.03±0.10 | 0.09 |
| Arginine, µM | −9.49±27.36 | −9.73±31.15 | 0.97 |
| Citrulline, µM | 0.28±6.44 | 1.39±7.74 | 0.48 |
| Cysteine, µM | 2.91±30.22 | 14.47±30.25 | 0.08 |
| Homocysteine, µM | 0.57±8.20 | 2.83±6.30 | 0.17 |
| Methionine, µM | 6.58±9.44 | 3.19±13.31 | 0.18 |
| S-adenosyl methionine, nM | −2.55±37.76 | −0.78±31.65 | 0.84 |
| S-adenosyl homocysteine, nM | −4.41±6.09 | −4.03±6.60 | 0.74 |
| 9-HODE, ng/ml | −2.05±6.25 | 1.01±3.3 | 0.02 |
| 13-HODE, ng/ml | −1.82±6.84 | 3.32±6.82 | 0.004 |
| 8-HETE, ng/ml | −0.02±0.09 | 0.04±0.17 | 0.14 |
| 11-HETE, ng/ml | −0.13±0.18 | −0.01±0.38 | 0.12 |
| 12-HETE, ng/ml | −0.79±2.94 | 2.15±11.50 | 0.18 |
| 15-HETE, ng/ml | −0.28±0.55 | 0.18±1.04 | 0.04 |
| 20-HETE, ng/ml | −0.05±0.17 | 0.00±0.11 | 0.15 |
| 15-HEPE, ng/ml | −0.03±0.05 | −0.01±0.03 | 0.15 |
Data are presented as the mean±SD. HODE, hydroxyoctadecadienoic acid; HETE, hydroxyeicosatetraenoic acid; HEPE, hydroxyeicosapentaenoic acid.